StockNews.AI
AZN
StockNews.AI
179 days

Lost Money on AstraZeneca PLC(AZN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

1. Lawsuit alleges AstraZeneca engaged in insurance fraud in China. Investors claim losses. 2. Complaint asserts false statements concealed legal risks. Business exposure worries arise. 3. China operations may face heightened legal issues. Detainment of China President mentioned.

4m saved
Insight
Article

FAQ

Why Bearish?

The lawsuit introduces legal uncertainty and reputational damage, potentially depressing AZN's share price. Similar legal challenges in the pharma sector have historically led to short-term declines.

How important is it?

The case directly targets AZN with potentially significant financial and operational risks, though outcome uncertainty tempers the overall impact.

Why Short Term?

Market reactions typically manifest quickly upon news of litigation. Prior cases show initial volatility until resolution or clarification occurs.

Related Companies

PFEMRKJNJBMY
NEW YORK, Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=130846&wire=4 AZN investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) AstraZeneca engaged in insurance fraud in China; (2) as a result, AstraZeneca faced heightened legal exposure in China, which eventually resulted in the AstraZeneca China President being detained by Chinese law enforcement authorities; (3) as a result, AstraZeneca understated its legal risks; (4) the foregoing, once revealed, could materially harm AstraZeneca's business activities in China; and (5) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. WHAT'S NEXT? If you suffered a loss in AstraZeneca during the relevant time frame, you have until February 21, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004[email protected]Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com SOURCE Levi & Korsinsky, LLP

Related News